Clinical trials
Myeloid Malignancy clinical trials
Below are recruiting myeloid malignancy clinical trials, each written for real people, not researchers. We’re tracking 85 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07014449RecruitingPhase 1
WBC100 capsule for relapsed or refractory AML
This trial tests an experimental capsule called WBC100 for people whose leukemia has come back or hasn't responded to standard treatments. It aims to see if the drug is safe and if it can help control the disease.
Hangzhou, ZhejiangAges 18 years+ - NCT07486713RecruitingPhase 4
Olutasidenib drug interaction study for IDH1 mutation cancers
This trial tests how olutasidenib interacts with other drugs in people with cancers that have an IDH1 mutation, like certain leukemias or brain tumors. Participation may help determine the best way to take this treatment safely.
Orange, CaliforniaAges 18 years+ - NCT02958462Recruiting
Clinic study for early blood or bone marrow warning signs
This study follows people who may have early, unclear blood count problems or certain genetic/immune patterns that can later lead to bone marrow failure or blood cancers. It may help doctors better understand risks over time and guide earlier care.
Scottsdale, ArizonaAges 18 years+ - NCT07032727RecruitingPhase 2
Olutasidenib plus targeted therapy for relapsed IDH1-mutated myeloid cancers
This trial tests a combination of olutasidenib with other targeted drugs for people with certain blood cancers that have returned or not responded to treatment. It focuses on patients who have both an IDH1 mutation and a second activating mutation in specific signaling genes.
Miami, FloridaAges 18 years+ - NCT07844694RecruitingPhase 1
Low-dose sirolimus for patients with RUNX1 platelet disorder
This trial tests whether a low dose of sirolimus, a drug that calms the immune system, can help improve blood counts and reduce bleeding risk in people with a genetic condition called RUNX1 familial platelet disorder. If it works, it might lower the chance of developing serious blood problems later.
Portland, OregonAges 18 years+ - NCT06737081RecruitingPhase 2
Study of an experimental anemia treatment for chemotherapy patients
This study tests a new medication (SAL-0951) for treating low red blood cell counts (anemia) caused by chemotherapy in people with certain types of cancer that are not curable. It may help improve energy and reduce the need for blood transfusions.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07263074Recruiting
Watching stories to help decide on a stem cell transplant
This study tests if watching short videos made by other people who faced the same decision can help you and your family feel more prepared when choosing whether to have a stem cell transplant (also called alloHCT) for your blood cancer.
Rochester, New YorkAges 21 years+ - NCT06656494RecruitingPhase 1
New drug combo for myeloid blood cancers
This trial tests a new drug (ICP-248) combined with standard treatment azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to find out if the combo is safe and effective for those who haven't been helped by other treatments or cannot have strong chemotherapy.
Orange, CaliforniaAges 18 years+ - NCT06090669RecruitingPhase 1
Trial of imatinib for people with RUNX1 deficiency
This trial tests if imatinib can help people with a genetic condition called RUNX1 deficiency, which causes bleeding problems. It aims to increase the activity of the RUNX1 gene to improve blood clotting.
Bethesda, MarylandAges 18–120 - NCT05588154Recruiting
Donate blood and other samples to study blood cancers
This study asks healthy adults to provide blood, bone marrow (if needed), skin, saliva, and stool samples. Scientists use these samples to compare patterns related to myeloid (bone-marrow) blood cancers, which may help future research and tests.
Bethesda, MarylandAges 18–120 - NCT05436561RecruitingPhase 2
Test a reduced transplant plan for older leukemia patients
This Phase 2 trial studies a “reduced-intensity” transplant plan for people age 55–65 who have certain blood cancers and a suitable donor. It may help older patients get the benefits of a transplant with less treatment burden, but it excludes people with serious organ problems or active infections.
Shanghai, Shanghai MunicipalityAges 55–65 - NCT04187703RecruitingEarly Phase 1
Testing azacitidine and decitabine for bone marrow cancers
This early-phase study tests whether combining two “epigenetic” medicines—azacitidine and decitabine—can improve outcomes for certain bone marrow cancers. It may help if you have a type of myelodysplastic syndrome (MDS) or MDS/MPN overlap that is expected to be sensitive to these medicines.
Cleveland, OhioAges 18 years+ - NCT03850418RecruitingPhase 2
Azacitidine for blood chimerism changes after transplant
This Phase 2 study tests whether azacitidine can improve outcomes when donor blood “chimerism” starts dropping after an allogeneic stem cell transplant. It’s for people with AML, MDS, MPN, or CMML who are experiencing early warning signs in their blood counts after transplant but without clear relapse in the bone marrow.
Detroit, MichiganAges 18–75 - NCT07366801RecruitingPhase 2/Phase 3
Preventing graft versus host disease in children with blood cancer
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
MoscowAges 1–25 - NCT03471260RecruitingPhase 1/Phase 2
Ivosidenib and venetoclax for IDH1-mutated leukemia or MDS
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT06550713RecruitingPhase 1
Testing TQB3455 tablets for blood cancers with IDH2 mutation
This trial tests a new tablet, TQB3455, for people with certain blood cancers (MDS or AML) that have an IDH2 mutation. The goal is to see if the drug can help when other treatments haven't worked or aren't possible.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06034275RecruitingPhase 1
Study of VIP943 for CD123-positive blood cancers
This trial tests a new drug called VIP943 for people with advanced acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), or myelodysplastic syndrome (MDS) whose cancer cells have a marker called CD123. It is for those who have tried all other treatments or cannot receive them.
Birmingham, AlabamaAges 18 years+ - NCT07147621Recruiting
Chemotherapy and thinking changes in blood cancer treatment
This study looks at whether chemotherapy for blood cancers like leukemia and lymphoma can affect thinking, memory, or concentration. It compares patients to a close family member or friend to see if any changes are related to the treatment.
Angers, Maine et LoireAges 18 years+ - NCT07154823Recruiting
Blood cancer registry study for biomarker discovery
This study collects samples and health information from people with certain blood cancers to learn more about the disease and find markers that may help guide future treatments. You will not receive a treatment from this study, but you may help advance research.
Iowa City, IowaAges birth+ - NCT07106749RecruitingPhase 1
CD180 car T cells for blood cancers that came back
This trial tests a new CAR T cell therapy that targets a protein called CD180 on cancer cells. It is for people with certain types of relapsed or refractory leukemia or lymphoma that has not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07109518RecruitingPhase 1
CD7 CAR T-Cell Therapy for Blood Cancers That Return or Don't Respond
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06629584RecruitingPhase 2
Asciminib for second-line chronic phase CML
This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.
Houston, TexasAges 18 years+ - NCT03802695RecruitingPhase 1
Orca-Q pill to help during stem cell transplant
This Phase 1 trial studies Orca-Q to see if it is safe and works when added around the time of an allogeneic (donor) stem cell transplant for certain blood cancers. If you qualify, the study may offer a new option for managing the transplant immune response.
Duarte, CaliforniaAges 12–78 - NCT06206174RecruitingPhase 1/Phase 2
Study of TGRX-814 for blood cancers
This trial tests a new drug called TGRX-814 for people with certain blood cancers like non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndromes. It aims to see if the drug is safe and effective.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new Myeloid Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myeloid malignancy?
- Yes. Clin2 currently lists 85 recruiting myeloid malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myeloid malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myeloid malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.